石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01093 石药集团

交易中 11-03 15:32:37

7.785

-0.110

-1.39%

最高7.950	最低7.740	成交量6,778万
今开7.855	昨收7.895	日振幅2.66%
总市值896.99亿	流通市值896.99亿	总股本115.22亿
成交额5.31亿	换手率0.59%	流通股本115.22亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01093","market":"HK","secType":"STK","nameCN":"石药集团","latestPrice":7.785,"timestamp":1793691155365,"preClose":7.895,"halted":0,"volume":67781865,"delay":0,"changeRate":-0.013932868904369783,"floatShares":11522000000,"shares":11522000000,"eps":0.3996494398066784,"marketStatus":"交易中","change":-0.11,"latestTime":"11-03 15:32:37","open":7.855,"high":7.95,"low":7.74,"amount":531183980,"amplitude":0.026599,"askPrice":7.79,"askSize":270000,"bidPrice":7.785,"bidSize":80000,"shortable":3,"etf":0,"ttmEps":0.7650887464301407,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1793693400000},"marketStatusCode":2,"adr":0,"listingDate":772128000000,"exchange":"SEHK","adjPreClose":7.895,"dividendRate":0.042428,"openAndCloseTimeList":[[1793669400000,1793678400000],[1793682000000,1793692800000]],"volumeRatio":0.877879,"optionData":{"bulkOrders":[{"symbol":"CSP.HK","call":true,"expireDate":1806336000000,"strike":"9.25","timestamp":1793687330867,"price":0.48,"volume":385,"amount":369600,"type":"*"},{"symbol":"CSP.HK","call":true,"expireDate":1795708800000,"strike":"8.50","timestamp":1793683953373,"price":0.17,"volume":225,"amount":76500,"type":"*"}]},"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"CSP.HK","impliedVol":0.5021,"impliedVolPercentile":0.5366},"requestUrl":"/m/hq/s/01093","defaultTab":"news","newsList":[{"id":"2680574790","title":"花旗：中国制药及生物科技ESMO数据再获验证 医药首选石药集团(01093.HK)及恒瑞医药(01276.HK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2680574790","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680574790?lang=zh_cn&edition=full","pubTime":"2026-11-03 09:32","pubTimestamp":1793669529,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BZ08YT58.USD","09939","LU1226287792.SGD","LU2039709279.SGD","LU1813983027.USD","LU0359201885.HKD","LU0880133367.SGD","LU0359201612.USD","LU1226288170.HKD","BK1191","LU0140636845.USD","LU0359202008.SGD","IE00BZ08YS42.EUR","LU0501845795.SGD","HK0000165453.HKD","KURE","LU0067412154.USD","01093","LU0072913022.USD","01477","IE00B543WZ88.USD","IE0008369823.USD","LU1951186391.HKD","LU1152091168.USD","LU2543165471.USD","BK1515","SG9999004220.SGD","IE00B5MMRT66.SGD","LU0326950275.SGD","LU1807302812.USD","BK1161","IE00B031HY20.USD","LU1226287875.USD","IE0008368742.USD","LU1960683339.HKD","BK1574","BK1521","LU1023057109.AUD","LU1226288253.USD","01276","IE00BZ08YR35.GBP","LU1226287529.USD","LU1993786604.SGD","LU1152091754.HKD","LU1328277881.USD","LU0314109678.HKD","LU0315179316.USD","LU1008478684.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161485849","title":"石药集团更新10月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1161485849","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161485849?lang=zh_cn&edition=full","pubTime":"2026-11-02 18:56","pubTimestamp":1793617010,"startTime":"0","endTime":"0","summary":"石药集团有限公司于2026年11月2日发布2026年10月股份变动月报表，报告期内公司股本保持不变。根据公告，截至2026年10月31日，公司已发行股份总数为11,522,451,732股，连续两个月保持相同规模，期末并无持有库存股且无新增发行或回购注销活动。石药集团承诺继续符合香港联交所上市规则规定的公众持股量要求。截至10月底，公司股本架构未发生变动。公司表示将持续遵守香港联交所《上市规则》及相关法律法规。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680755304","title":"石药集团(01093)：普卢格列汀片联合达格列净片及盐酸二甲双胍缓释片治疗2型糖尿病的III期临床试验取得积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2680755304","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680755304?lang=zh_cn&edition=full","pubTime":"2026-11-02 18:52","pubTimestamp":1793616728,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，本集团开发的普卢格列汀片(该产品)于近日在普卢格列汀、达格列净及二甲双胍三药联合治疗2型糖尿病患者的III期临床试验中获得顶线分析数据。统计分析表明，普卢格列汀、达格列净及二甲双胍三药联合治疗24周后，患者HbA1c较基线的降幅显著优于达格列净联合二甲双胍或普卢格列汀联合二甲双胍的治疗组。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1517287.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1226288170.HKD","LU0067412154.USD","LU1152091754.HKD","BK1191","BK1515","MDTX","PSYK","LU0315179316.USD","LU1226287529.USD","LU1008478684.HKD","LU0140636845.USD","LU1951186391.HKD","LU1152091168.USD","LU0326950275.SGD","LU0880133367.SGD","LU2039709279.SGD","LU1807302812.USD","KURE","LU0314109678.HKD","IE00BZ08YR35.GBP","HK0000165453.HKD","LU1328277881.USD","IE00B543WZ88.USD","SG9999004220.SGD","IE00BZ08YT58.USD","IBBQ","IE00B5MMRT66.SGD","IE0008368742.USD","LU1813983027.USD","LU1226287792.SGD","LU1960683339.HKD","IBBJ","LU0501845795.SGD","BK1521","IE0008369823.USD","LU0072913022.USD","LU1993786604.SGD","LU1226287875.USD","LU1226288253.USD","IE00BZ08YS42.EUR","01093","BMED","IE00B031HY20.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177604608","title":"石药集团(01093)在华启动SYS 6057重组RSV疫苗I期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1177604608","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177604608?lang=zh_cn&edition=full","pubTime":"2026-11-02 18:51","pubTimestamp":1793616699,"startTime":"0","endTime":"0","summary":"2026年11月2日，石药集团有限公司发布自愿公告称，其自主研发的SYS 6057重组呼吸道合胞病毒疫苗I期临床试验已在中国正式启动。此次试验采用随机、盲法、安慰剂对照设计，计划评估该疫苗在18岁及以上人群中的安全性及免疫原性，目前受试者的招募与筛选工作正在进行中。公告显示，SYS 6057针对RSV A和B两种亚型表现出良好的攻毒保护作用，具备较高中和抗体活性，且免疫保护作用持续时间较长。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151044988","title":"石药集团（01093）重组带状疱疹病毒疫苗SYS 6052在中国启动I/II期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1151044988","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151044988?lang=zh_cn&edition=full","pubTime":"2026-11-02 18:51","pubTimestamp":1793616686,"startTime":"0","endTime":"0","summary":"石药集团有限公司11月2日发布自愿性公告称，由集团自主研发的重组带状疱疹病毒疫苗SYS 6052已在中国正式启动I/II期临床试验。根据公告，石药集团已于2026年7月收到国家药品监督管理局签发的《药物临床试验批准通知书》，并在获批后开展随机、盲法、对照的I/II期临床试验，以评估该疫苗在40岁及以上人群中的安全性与免疫原性。石药集团表示，将按相关法规要求持续推进临床研究，并在后续阶段及时披露进展信息。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145458081","title":"石药集团（01093）旗下普卢格列汀三药联用III期临床达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1145458081","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145458081?lang=zh_cn&edition=full","pubTime":"2026-11-02 18:50","pubTimestamp":1793616646,"startTime":"0","endTime":"0","summary":"2026年11月2日，石药集团有限公司发布自愿公告称，其开发的二肽基肽酶-Ⅳ抑制剂普卢格列汀片，在与达格列净片及盐酸二甲双胍缓释片三药联合治疗2型糖尿病的III期临床试验中取得积极顶线结果。公告显示，三药联合方案在24周时显著优于达格列净联合二甲双胍组及普卢格列汀联合二甲双胍组，实现预设主要终点。石药集团董事会主席蔡东晨已在公告上签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680755939","title":"石药集团：重组呼吸道合胞病毒疫苗一期临床试验正式启动","url":"https://stock-news.laohu8.com/highlight/detail?id=2680755939","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680755939?lang=zh_cn&edition=full","pubTime":"2026-11-02 18:46","pubTimestamp":1793616360,"startTime":"0","endTime":"0","summary":"南财智讯11月2日电，石药集团（01093.HK）发布自愿公告，公司开发的重组呼吸道合胞病毒疫苗（中国仓鼠卵巢细胞）的一期临床试验已在中国正式启动。该产品临床前研究已全面完成，对呼吸道合胞病毒两种亚型均具有良好的攻毒保护作用，展现出较高的中和抗体活性，且免疫保护作用持久。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611023918873284.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611023918873284.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159646","MDTX","BK1521","LU1008478684.HKD","LU1960683339.HKD","LU1226287529.USD","BK1515","01093","LU1951186391.HKD","IE00B5MMRT66.SGD","LU1226288170.HKD","LU0072913022.USD","LU2039709279.SGD","HK0000165453.HKD","LU0315179316.USD","IBBQ","LU0067412154.USD","LU0880133367.SGD","IE00BZ08YT58.USD","LU0326950275.SGD","IE0008368742.USD","IE00B031HY20.USD","LU0314109678.HKD","IE00B543WZ88.USD","LU1328277881.USD","LU1152091168.USD","LU1807302812.USD","LU1226287792.SGD","SG9999004220.SGD","LU1226287875.USD","LU1993786604.SGD","PSYK","BMED","IE0008369823.USD","BK1191","LU1813983027.USD","IE00BZ08YR35.GBP","LU1226288253.USD","IBBJ","LU0501845795.SGD","LU0140636845.USD","LU1152091754.HKD","KURE","IE00BZ08YS42.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680755835","title":"石药集团(01093.HK)：SYS6057(重组呼吸道合胞病毒疫苗(CHO细胞))的I期临床试验在中国正式启动","url":"https://stock-news.laohu8.com/highlight/detail?id=2680755835","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680755835?lang=zh_cn&edition=full","pubTime":"2026-11-02 18:46","pubTimestamp":1793616360,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00B031HY20.USD","LU0067412154.USD","IE0008369823.USD","LU0880133367.SGD","01093","BK1521","HK0000165453.HKD","KURE","IE00BZ08YT58.USD","LU0326950275.SGD","LU2039709279.SGD","LU0315179316.USD","IE00B543WZ88.USD","LU1152091754.HKD","LU1226288170.HKD","LU1008478684.HKD","LU1152091168.USD","LU1226287529.USD","LU1226288253.USD","LU1813983027.USD","IE00BZ08YS42.EUR","LU1951186391.HKD","LU1226287875.USD","IE00BZ08YR35.GBP","BK1515","LU1993786604.SGD","LU1807302812.USD","IE00B5MMRT66.SGD","LU0072913022.USD","SG9999004220.SGD","LU1960683339.HKD","LU0314109678.HKD","LU1328277881.USD","LU0501845795.SGD","IE0008368742.USD","BK1191","LU1226287792.SGD","LU0140636845.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680717785","title":"【券商聚焦】中信证券：国内医药板块业绩持续修复","url":"https://stock-news.laohu8.com/highlight/detail?id=2680717785","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680717785?lang=zh_cn&edition=full","pubTime":"2026-11-02 08:40","pubTimestamp":1793580014,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券发布2027年医疗健康行业投资策略，“十五五”开局之年，医药行业首次列为国家新兴支柱产业，紧随其后的价格机制优化改革 、支持创新药械高定价、以及推动商业医疗保险发展等行业增量改革政策趋势，叠加国内医药行业在创新领域集中兑现等产业内外催化因素驱动下，该机构看到2026H1国内医药板块业绩持续修复，尤其是创新药、创新器械等新兴产业板块。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994936","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160","159938","06990","LU0039217434.USD","LU0455707207.USD","LU0348825331.USD","02162","06996","LU0979878070.USD","IE00B031HY20.USD","BK0028","02268","01530","03692","01177","HK0000320264.USD","LU1969619763.USD","01952","09939","01276","01548","02269","LU1226287529.USD","02596","06821","01093","09926","LU0823426480.USD","01951","00013","09996","03759","LU2488822045.USD","LU0828237510.HKD","06030","LU1064131003.USD","KCE","06078","LU0607220059.USD","KURE","LU0708995153.HKD","01801","LU1794554557.SGD","09966","02096","02273","600030","LU0708995583.HKD","LU0348766576.USD","LU0588546209.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679976172","title":"石药集团(01093.HK)：SYS6043用于治疗晚期实体瘤的I / II期临床试验在中国首家中心正式启动","url":"https://stock-news.laohu8.com/highlight/detail?id=2679976172","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679976172?lang=zh_cn&edition=full","pubTime":"2026-10-30 18:37","pubTimestamp":1793356655,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1152091168.USD","LU0314109678.HKD","LU1226287529.USD","LU1328277881.USD","LU1960683339.HKD","IE00B543WZ88.USD","IE0008369823.USD","BK1521","BK1515","LU1807302812.USD","IE00BZ08YT58.USD","LU1951186391.HKD","LU0140636845.USD","LU1008478684.HKD","LU0067412154.USD","IE00B5MMRT66.SGD","SG9999004220.SGD","IE00B031HY20.USD","LU1152091754.HKD","LU2039709279.SGD","IE0008368742.USD","HK0000165453.HKD","LU1813983027.USD","LU1226288253.USD","LU1226287792.SGD","LU0315179316.USD","IE00BZ08YR35.GBP","LU0880133367.SGD","BK1191","LU0501845795.SGD","LU1993786604.SGD","KURE","01093","LU0072913022.USD","IE00BZ08YS42.EUR","LU0326950275.SGD","LU1226288170.HKD","LU1226287875.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122258748","title":"石药集团（01093）启动SYS 6043治疗晚期实体瘤I/II期中国首家临床中心","url":"https://stock-news.laohu8.com/highlight/detail?id=1122258748","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122258748?lang=zh_cn&edition=full","pubTime":"2026-10-30 18:36","pubTimestamp":1793356579,"startTime":"0","endTime":"0","summary":"石药集团有限公司10月30日公告称，公司及其附属公司自主研发的靶向B7-H3抗体偶联药物SYS 6043已在中国正式启动首家中心的I/II期临床试验。该多中心、开放性I/II期试验将评估SYS 6043单药或联合贝伐珠单抗及╱或化疗在晚期实体瘤受试者中的安全性、耐受性、药代动力学特征及初步疗效。石药集团表示，后续将根据临床结果推进相关研发工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134323482","title":"石药集团2026年第三季度营收7.36亿元，经调整净利润-0.74亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1134323482","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134323482?lang=zh_cn&edition=full","pubTime":"2026-10-28 18:31","pubTimestamp":1793183516,"startTime":"0","endTime":"0","summary":"2026年第三季度，石药集团实现营收7.36亿元，同比增长35.47%。经调整净利润为-0.74亿元，同比下降211.72%。从今年前九个月来看，公司营收累计达39.76亿元，较去年同期增长149.62%。同期经调整净利润累计为11.52亿元，较上年同期增长1877.40%。期内经营活动产生的现金流量净额达26.71亿元，同比大幅提升1625.26%。财报显示，报告期内巨石生物与阿斯利康签署战略合作与授权协议并确认了大额收入，为公司整体营收贡献显著增量。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188100471","title":"石药集团（01093）SYS 6077注射液在中国首家研究中心启动I期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1188100471","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188100471?lang=zh_cn&edition=full","pubTime":"2026-10-28 18:31","pubTimestamp":1793183496,"startTime":"0","endTime":"0","summary":"2026年10月28日，石药集团有限公司公告，其自主研发的SYS 6077注射液用于治疗晚期恶性肿瘤的I期临床试验已在中国首家研究中心正式启动。该项目目前正积极推进受试者招募与筛选工作。本次I期临床试验为多中心研究，旨在评估SYS 6077注射液在恶性肿瘤患者中的安全性、耐受性、免疫原性、药代动力学特征及初步抗肿瘤活性。石药集团已于2026年9月获得中华人民共和国国家药品监督管理局签发的《药物临床试验批准通知书》，并随即启动该临床试验。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678333463","title":"石药集团(01093.HK)：石药创新前三季度归母净利润12.1亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2678333463","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678333463?lang=zh_cn&edition=full","pubTime":"2026-10-28 18:26","pubTimestamp":1793183219,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00B543WZ88.USD","HK0000165453.HKD","LU1993786604.SGD","LU1226287792.SGD","LU1960683339.HKD","LU1951186391.HKD","LU1226287875.USD","LU1152091168.USD","KURE","LU1226287529.USD","IE00BZ08YT58.USD","LU1807302812.USD","LU1152091754.HKD","LU1008478684.HKD","LU0072913022.USD","LU1226288253.USD","BK1515","LU0326950275.SGD","IE00BZ08YS42.EUR","LU0315179316.USD","IE00B031HY20.USD","BK1191","LU0140636845.USD","LU1328277881.USD","SG9999004220.SGD","IE00B5MMRT66.SGD","IE00BZ08YR35.GBP","LU0501845795.SGD","LU0880133367.SGD","LU1813983027.USD","BK1521","LU0067412154.USD","LU1226288170.HKD","01093","IE0008369823.USD","IE0008368742.USD","LU0314109678.HKD","LU2039709279.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678633314","title":"石药集团(01093.HK)：SYS6077注射液用于治疗晚期恶性肿瘤的I期临床试验在中国首家研究中心正式启动","url":"https://stock-news.laohu8.com/highlight/detail?id=2678633314","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678633314?lang=zh_cn&edition=full","pubTime":"2026-10-28 18:25","pubTimestamp":1793183105,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00B031HY20.USD","LU0880133367.SGD","LU1226288253.USD","BK1521","LU0072913022.USD","LU1008478684.HKD","IE0008369823.USD","LU1226287875.USD","LU1807302812.USD","LU1226287792.SGD","IE00BZ08YS42.EUR","LU0315179316.USD","HK0000165453.HKD","SG9999004220.SGD","LU0314109678.HKD","LU1226288170.HKD","KURE","LU1960683339.HKD","LU1152091754.HKD","LU1152091168.USD","LU0501845795.SGD","01093","LU1328277881.USD","IE00BZ08YR35.GBP","LU0326950275.SGD","IE00B5MMRT66.SGD","LU0140636845.USD","IE0008368742.USD","LU0067412154.USD","LU1226287529.USD","LU1951186391.HKD","LU2039709279.SGD","LU1993786604.SGD","BK1515","LU1813983027.USD","BK1191","IE00BZ08YT58.USD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678459668","title":"里昂：中国医疗健康板块近期回调属买入机会 海外及内地趋势改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2678459668","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678459668?lang=zh_cn&edition=full","pubTime":"2026-10-28 16:03","pubTimestamp":1793174593,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，里昂发布研报称，中国医疗健康板块近期回调主要受宏观忧虑推动，相关因素大致已反映于股价;海外进展及内地营运持续改善，宏观环境亦已企稳，该行视近期回调为买入机会。于ESMO 2026，中国资产占96项LBA中的29项，以及12场Presidential Symposium中的5场。该行维持中国医疗健康股票篮子不变，指医疗健康占基金总持仓不足2%，估值折让提供更具吸引力的长线买入机会;进一步海外临床进展及新的III期资产BD交易亦应为板块提供支持。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1514114.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1589","01801","09926","01093","IE00BZ08YS42.EUR","LU0561508036.HKD","LU1008478684.HKD","LU0417516571.SGD","LU0417516902.SGD","BK1574","02595","LU1226287875.USD","LU1328277881.USD","BK4588","LU1813983027.USD","BK1521","LU1969619763.USD","BK4581","LU0196878994.USD","KURE","LU0348783233.USD","LU1226288253.USD","159760","BK1191","LU0417516738.SGD","LU2097828631.EUR","BK1583","XLV","LU2399975544.HKD","LU0607220059.USD","LU2476274720.SGD","LU2328871848.SGD","LU0326950275.SGD","IXJ","XBI","BK4550","LU2488822045.USD","LU0501845795.SGD","09887","LABU","LU2097828805.USD","LU1226288170.HKD","LU0348766576.USD","VHT","LU1993786604.SGD","IE00B031HY20.USD","IE0008369823.USD","06990","IE00BPRC5H50.USD","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162259855","title":"石药集团（01093）发布SYS 6043治疗晚期乳腺癌I/II期临床积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1162259855","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162259855?lang=zh_cn&edition=full","pubTime":"2026-10-27 18:53","pubTimestamp":1793098388,"startTime":"0","endTime":"0","summary":"2026年10月27日，石药集团有限公司公告称，其自主研发的B7-H3靶向抗体偶联药物SYS 6043用于晚期乳腺癌的I/II期临床研究结果已于2026年10月26日在2026年欧洲肿瘤内科学会年会上以快速口头报告形式公布。研究为多中心、开放标签设计，旨在评估SYS 6043在晚期实体瘤患者中的安全性、耐受性、药代动力学及初步疗效。公告指出，SYS 6043在经治晚期乳腺癌患者中展现了可控的安全性与持久的抗肿瘤活性，支持在6 mg/kg每三周一次剂量下开展进一步研究。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153860815","title":"石药集团（01093.HK）PD-1/IL-15双功能融合蛋白SYS 6090 I/II期临床数据亮相2026年ESMO年会","url":"https://stock-news.laohu8.com/highlight/detail?id=1153860815","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153860815?lang=zh_cn&edition=full","pubTime":"2026-10-27 18:52","pubTimestamp":1793098360,"startTime":"0","endTime":"0","summary":"2026年10月27日，石药集团有限公司发布自愿公告称，由公司自主研发的抗程序性死亡受体1/白细胞介素-15双功能融合蛋白SYS 6090在晚期实体瘤患者中的首次人体I/II期临床研究结果，于2026年10月25日在2026年欧洲肿瘤内科学会年会上以“快速口头报告”形式公布。本次研究为开放标签、多中心I/II期临床试验，适用对象为经标准治疗进展或不耐受的晚期恶性实体瘤患者。主要终点包括安全性、客观缓解率和药代动力学；数据截至2026年4月13日。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678175115","title":"石药集团(01093.HK)：SYS6043(B7-H3 ADC)用于治疗晚期乳腺癌的I/II期临床研究结果于2026年ESMO年会以快速口头报告形式公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2678175115","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678175115?lang=zh_cn&edition=full","pubTime":"2026-10-27 18:51","pubTimestamp":1793098265,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE0008369823.USD","LU0072913022.USD","LU0326950275.SGD","LU1008478684.HKD","LU1807302812.USD","LU1226287875.USD","LU0501845795.SGD","LU0880133367.SGD","SG9999004220.SGD","LU0315179316.USD","LU1951186391.HKD","BK1521","LU1226287792.SGD","LU0067412154.USD","LU1328277881.USD","IE00BZ08YR35.GBP","01093","KURE","LU1152091754.HKD","LU1226288253.USD","BK1515","HK0000165453.HKD","LU0140636845.USD","IE0008368742.USD","LU1993786604.SGD","LU1226287529.USD","LU0314109678.HKD","IE00B5MMRT66.SGD","LU1813983027.USD","LU1226288170.HKD","IE00BZ08YT58.USD","LU1152091168.USD","LU1960683339.HKD","LU2039709279.SGD","BK1191","IE00B031HY20.USD","IE00BZ08YS42.EUR","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678756811","title":"石药集团(01093)：抗PD-1/IL-15双功能融合蛋白SYS6090 (JMT108) 单药治疗晚期实体瘤的I/II期临床研究结果于2026年ESMO年会上以快速口头报告形式公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2678756811","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678756811?lang=zh_cn&edition=full","pubTime":"2026-10-27 18:49","pubTimestamp":1793098146,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，由本集团开发的抗程序性死亡受体1╱白细胞介素-15的双功能融合蛋白SYS6090(该产品)，在晚期实体瘤患者中开展的首次人体I/II期临床研究(该研究)结果，已于2026年10月25日在2026年欧洲肿瘤内科学会年会上以快速口头报告形式公布。本次汇报数据截止日期为2026年4月13日。在可评价的HCC和CRC患者中，ORR分别达到40.0%和21.1%。上述结果支持在CRC、 HCC及其他瘤种中进一步评价该产品的临床价值。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1513468.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1521","BK1515","IE00B031HY20.USD","IE00B543WZ88.USD","IE0008369823.USD","LU0314109678.HKD","LU0315179316.USD","LU1152091754.HKD","LU1226287529.USD","BK1191","IE00BZ08YS42.EUR","LU1951186391.HKD","KURE","LU1008478684.HKD","LU1226288170.HKD","IE0008368742.USD","LU1328277881.USD","IE00BZ08YT58.USD","LU0501845795.SGD","LU1807302812.USD","SG9999004220.SGD","LU1960683339.HKD","LU0880133367.SGD","LU2039709279.SGD","IE00B5MMRT66.SGD","LU1993786604.SGD","LU0067412154.USD","LU1226287792.SGD","LU1226287875.USD","LU1813983027.USD","LU1226288253.USD","HK0000165453.HKD","LU0140636845.USD","LU0326950275.SGD","LU1152091168.USD","LU0072913022.USD","IE00BZ08YR35.GBP","01093"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cspc.com.hk","stockEarnings":[{"period":"1week","weight":-0.0407},{"period":"1month","weight":-0.1885},{"period":"3month","weight":-0.0503},{"period":"6month","weight":-0.0001},{"period":"1year","weight":0.0769},{"period":"ytd","weight":-0.0227}],"compareEarnings":[{"period":"1week","weight":0.0078},{"period":"1month","weight":-0.0242},{"period":"3month","weight":-0.0951},{"period":"6month","weight":-0.1076},{"period":"1year","weight":-0.097},{"period":"ytd","weight":-0.0873}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"石药集团有限公司是一家主要从事药品的生产及销售的公司。该公司主要从事成药业务、原料产品业务、功能食品及其他业务。该公司的产品主要涵盖神经系统、抗肿瘤、抗感染、心血管、呼吸系统、消化代谢以及其他治疗领域。该公司的产品销往国内外市场。","yearOnYearQuotes":[{"month":1,"riseRate":0.53125,"avgChangeRate":0.00944},{"month":2,"riseRate":0.75,"avgChangeRate":0.095107},{"month":3,"riseRate":0.46875,"avgChangeRate":0.017429},{"month":4,"riseRate":0.59375,"avgChangeRate":0.057786},{"month":5,"riseRate":0.59375,"avgChangeRate":0.042699},{"month":6,"riseRate":0.3125,"avgChangeRate":0.001865},{"month":7,"riseRate":0.393939,"avgChangeRate":0.015797},{"month":8,"riseRate":0.454545,"avgChangeRate":0.011796},{"month":9,"riseRate":0.515152,"avgChangeRate":0.003034},{"month":10,"riseRate":0.545455,"avgChangeRate":0.00373},{"month":11,"riseRate":0.484848,"avgChangeRate":0.006441},{"month":12,"riseRate":0.5,"avgChangeRate":-0.013214}],"exchange":"SEHK","name":"石药集团","nameEN":"CSPC PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供石药集团(01093)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"石药集团,01093,石药集团股票,石药集团股票老虎,石药集团股票老虎国际,石药集团行情,石药集团股票行情,石药集团股价,石药集团股市,石药集团股票价格,石药集团股票交易,石药集团股票购买,石药集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供石药集团(01093)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}